Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erbitux and Novantrone in metastatic AIPC
NCT00661492Phase 2Completed
- Sponsor
- US Oncology Network
- Start
- May 2008
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KL-140 in prostate cancer (PCa), sponsored by US Oncology Network. Primary endpoint: Time to Progression at 24 months. Started May 2008; status: completed.
02
Drugs
KL-140
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00661492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661492.